In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ACNAP Silver Members, Fellows of the ESC and Young combined Members

"Heart failure: across-sectional study about quality of life, anxiety depresion and detection of possible health and cardiovascular problems"

Session Poster Session 2

Speaker Rafael Mesa Rico

Congress : EuroHeartCare 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure - Treatment
  • Session type : Poster Session
  • FP Number : P236

Authors : E Marques-Sule (Valencia,ES), M Romero Fuentes (Valencia,ES), S Senra (Basingstoke,GB), L Almenar (Valencia,ES), R Lopez Vilella (Valencia,ES), S Perez-Alenda (Valencia,ES), F Querol-Fuentes (Valencia,ES), R Mesa Rico (Marbella,ES), AL Fernadez Oliver (Malaga,ES)

Authors:
E Marques-Sule1 , M Romero Fuentes1 , S Senra2 , L Almenar3 , R Lopez Vilella3 , S Perez-Alenda3 , F Querol-Fuentes1 , R Mesa Rico4 , AL Fernadez Oliver5 , 1University of Valencia, Physio-therapy - Valencia - Spain , 2Basingstoke and North Hamphire Hospital, Research and Development - Basingstoke - United Kingdom of Great Britain & Northern Ireland , 3University Hospital La Fe, Heart failure and heart transplant unit - Valencia - Spain , 4Hospital Costa del Sol - Marbella - Spain , 5University Hospital Virgen de la Victoria - Malaga - Spain ,

Citation:

Background: Quality of life, anxiety, depression and detection of health and cardiovascular complications are very important parameters in patients with heart failure (HF) that require the initiation of a physical activity (PA) program.

Purpose: This study aimed at measuring the quality of life, anxiety and depression levels in patients diagnosed with HF, as well as detecting other underlying general health and cardiovascular problems in order to recommend consulting a health professional prior to initiating a PA program.

Method: A cross-sectional study was performed in outpatients with a diagnostic of HF (n=110). This study complies with the Declaration of Helsinki and was approved by the Regional Ethics Committee. The quality of life was measured via Short-From 36. Anxiety and depression levels were measured with the Hospital Anxiety and Depression Scale. The detection of health and cardiovascular problems in patients willing to start a PA program were measured with the Physical Activity Readiness Questionnaire PAR-Q.

Results: The less affected domains for quality of life were physical function, general health, vitality and emotional role, while the most affected domains were physical pain, social function, mental health and physical role. It was found that 43.2% of participants had a good quality of life. Conversely, 22% of participants showed a high level of anxiety, whilst 12.2% presented a high level of depression. Finally, only 37% were allowed to perform PA without consulting a health professional, while 63% were recommended to consult a health professional prior to initiating any sort of PA.

Conclusion: The quality of life of HF patients was low and the most affected domains were physical pain, social function, mental health and physical role. Anxiety and depression levels were low, although anxiety was more present than depression. 63% of participants required professional input by a health professional prior to starting any PA.



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are